Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus.
Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non-insulin-dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose-fatty acid cycle toward a more normal level in NIDDM patients and in non-diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients.
Vesell
E S
ES
Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey 17033.
Chambers
C E
CE
Passananti
G T
GT
Demers
L M
LM
Beyer
K H
KH
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D015536:Down-Regulation; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D005951:Glucose Tolerance Test; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology*; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000494:pharmacology*; D014511:Uremia / Q000188:drug therapy
D001786:Blood Glucose; D005227:Fatty Acids; D006146:Guanidines; D007328:Insulin; D011719:Pyrazines; D006852:Hydrochlorothiazide; C056104:2-pyrazinoylguanidine